Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience
- PMID: 16778260
- PMCID: PMC7094735
- DOI: 10.1378/chest.129.6.1441
Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience
Abstract
Study objective: To investigate the efficacy and safety profiles of corticosteroid therapy in severe acute respiratory syndrome (SARS) patients.
Design: Four hundred one of 1,278 SARS cases treated in Guangzhou China between December 2002 and June 2003 fulfilled the diagnostic criteria issued by the World Health Organization for confirmed identification of SARS. Among them, the diagnosis of critical SARS was defined by criteria of SARS guidelines incorporated with a low oxygenation index (OI) [< 300 mm Hg]. Data of these patients retrieved from a database were retrospectively analyzed by logistic regression and Cox regression for the effect of corticosteroid therapy on death, hospitalization days, and complication presentation.
Results: Among the 401 SARS patients studied, 147 of 249 noncritical patients (59.0%) received corticosteroids (mean daily dose, 105.3 +/- 86.1 mg) [+/- SD], and all survived the disease; 121 of 152 critical patients (79.6%) received corticosteroids at a mean daily dose of 133.5 +/- 102.3 mg, and 25 died. Analysis of these 401 confirmed cases did not show any benefits of corticosteroid on the death rate and hospitalization days. However, when focused on 152 critical SARS cases, factors correlated with these end points indicated by univariate analysis included use of corticosteroid, age, rigor at onset, secondary respiratory infections, pulmonary rales, grading of OI, and use of invasive ventilation. After adjustment for possible confounders, treatment with corticosteroid was shown contributing to lower overall mortality, instant mortality, and shorter hospitalization stay (p < 0.05). Incidence of complications was significantly associated with the need for invasive ventilation but not with use of corticosteroids.
Conclusion: This Guangzhou retrospective study revealed that proper use of corticosteroid in confirmed critical SARS resulted in lowered mortality and shorter hospitalization stay, and was not associated with significant secondary lower respiratory infection and other complications.
Figures
Similar articles
-
[Evaluation of the efficacy and safety of corticosteroid in the treatment of severe SARS in Guangdong province with multi-factor regression analysis].Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2008 Feb;20(2):84-7. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2008. PMID: 18279590 Chinese.
-
[Retrospective discriminant analysis of the clinical diagnostic criteria for serious contagious severe acute respiratory syndrome].Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006 Jun;18(6):346-9. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006. PMID: 16784560 Chinese.
-
[Clinical therapy of severe acute respiratory syndrome: 38 cases retrospective analysis].Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003 Jun;15(6):343-5. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003. PMID: 12837165 Chinese.
-
Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS).Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004882. doi: 10.1002/14651858.CD004882.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2012 Oct 17;10:CD004882. doi: 10.1002/14651858.CD004882.pub3 PMID: 16437501 Updated. Review.
-
Severe acute respiratory distress syndrome (SARS): a critical care perspective.Crit Care Med. 2003 Nov;31(11):2684-92. doi: 10.1097/01.CCM.0000091929.51288.5F. Crit Care Med. 2003. PMID: 14605542 Review.
Cited by
-
Glucocorticoids Should Be Used With Caution in Patients With SARS-CoV-2.Front Med (Lausanne). 2021 Feb 24;8:564943. doi: 10.3389/fmed.2021.564943. eCollection 2021. Front Med (Lausanne). 2021. Retraction in: Front Med (Lausanne). 2022 May 31;9:947016. doi: 10.3389/fmed.2022.947016 PMID: 33718395 Free PMC article. Retracted.
-
SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions.Mol Cell Biochem. 2021 Feb;476(2):675-687. doi: 10.1007/s11010-020-03935-z. Epub 2020 Oct 16. Mol Cell Biochem. 2021. PMID: 33064288 Free PMC article. Review.
-
Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China.Infect Dis Poverty. 2020 Jul 8;9(1):85. doi: 10.1186/s40249-020-00710-6. Infect Dis Poverty. 2020. PMID: 32641121 Free PMC article.
-
Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis.J Clin Med. 2020 Jul 27;9(8):2392. doi: 10.3390/jcm9082392. J Clin Med. 2020. PMID: 32726951 Free PMC article.
-
Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients.Biol Blood Marrow Transplant. 2020 Nov;26(11):1983-1994. doi: 10.1016/j.bbmt.2020.07.027. Epub 2020 Jul 28. Biol Blood Marrow Transplant. 2020. PMID: 32736007 Free PMC article.
References
-
- Drosten C, Gunther S, Preiser W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976. - PubMed
-
- World Health Organization. SARS: cumulative number of reported probable cases. Available at: www.who.int/csr/sars/country/en/ Accessed January 24, 2004.
-
- Zhao Z, Zhang F, Xu M. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003;52(Pt 8):715–720. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous